Garrett Winslow
Algemeen Adviseur bij GALECTO, INC.
Vermogen: 2 432 $ op 31-05-2024
Oorsprong van het eerstegraads netwerk van Garrett Winslow
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
| Extinct | Pharmaceuticals: Major | 19 | |
| Public Company | Pharmaceuticals: Major | 13 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Garrett Winslow via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
| F-STAR THERAPEUTICS, INC. | Pharmaceuticals: Major | Director of Finance/CFO Director/Board Member Director/Board Member Chairman Chief Executive Officer Director/Board Member Director/Board Member Chief Tech/Sci/R&D Officer Chief Executive Officer | |
Galecto Biotech ApS
 Galecto Biotech ApS Pharmaceuticals: MajorHealth Technology Galecto Biotech ApS provides galectin modulators for the treatment of severe diseases, including fibrosis and cancer. Its products include galectin-3 inhibitors, fibrosis and literature. The company was founded by Tariq Sethi, Hans Thalsgard Schambye, Ulf Jorgen Nilsson, and Hakon Leffler in 2011 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member Chief Operating Officer Director/Board Member Chief Executive Officer | |
F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH
 F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH Medical SpecialtiesHealth Technology F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH develops improved therapeutic antibodies and antibody fragments for cancer. It is a biopharmaceutical company dedicated to developing novel bispecific antibody products that significantly improve on the current standard of care for patients with serious diseases such as cancer. The firm's modular antibody technology allows them to rapidly discover and develop bispecific antibodies by introducing additional binding sites to the constant region of an antibody. The company was founded by Florian Ruker, Gordana Wozniak-Knopp, and Gottfried Himmler on June 12, 2006 and is headquartered in Vienna, Austria. | Medical Specialties | Director/Board Member Director/Board Member Chairman Chief Executive Officer Director/Board Member | |
F-star Therapeutics Ltd.
 F-star Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology F-Star Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of immune-oncology drugs for antibody therapies. The company was founded in 2006 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Chairman Chief Executive Officer Director/Board Member Director/Board Member | |
F-star Biotechnology Ltd.
 F-star Biotechnology Ltd. BiotechnologyHealth Technology F-Star Biotechnology Ltd. is a biopharmaceutical company. It discovers, develops, and manufactures bispecific antibody products. The company is headquartered in Cambridge, the United Kingdom. | Biotechnology | Director/Board Member Director/Board Member Chairman Chief Executive Officer Director/Board Member | |
F-star Alpha Ltd.
 F-star Alpha Ltd. BiotechnologyHealth Technology F-star Alpha Ltd. develops novel bispecific antibody products. It focuses on treatment of breast and gastric cancer among a population of HER2-positive patients who do not respond or become resistant to current therapies. The company was founded in October 2013 and is headquartered in Cambridge, the United Kingdom. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member Chief Tech/Sci/R&D Officer | |
| NOVO NORDISK A/S | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| Technical University of Denmark | College/University | Graduate Degree Undergraduate Degree Graduate Degree | |
F-Star Beta Ltd.
 F-Star Beta Ltd. BiotechnologyHealth Technology F-Star Beta Ltd. is a biopharmaceutical company that focused in the development of oncology and immune-oncology products. The company was founded on October 14, 2014 and is headquartered in Cambridge, the United Kingdom. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
F-Star Delta Ltd.
 F-Star Delta Ltd. Pharmaceuticals: MajorHealth Technology Part of Sino Biopharmaceutical Ltd., F-Star Delta Ltd. develops antibody products to improve the treatment of serious diseases. The company is based in Cambridge, UK and was founded in 2016. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
| GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
IO Biotech ApS
 IO Biotech ApS BiotechnologyHealth Technology IO Biotech ApS operates as a clinical stage biotech company. It develops immunotherapy for cancer by targeting a mechanism used by tumour cells to evade immune responses. The company was founded by Mai-Britt Zocca, Mads Hald Andersen, Inge Marie Svane, Anders Ljungqvist and Per Thor Straten and is headquartered in Copenhagen, Denmark. | Biotechnology | Director/Board Member Chairman | |
| Harvard Medical School | College/University | Corporate Officer/Principal Doctorate Degree | |
Novo Seeds
 Novo Seeds Investment ManagersFinance Novo Seeds (Novo Seeds) is a venture capital operating division of Novo Nordisk Fonden. The firm was established in 2007, and is headquartered in Hellerup, Denmark. | Investment Managers | Private Equity Investor Director of Investments | |
EpiTherapeutics ApS
 EpiTherapeutics ApS BiotechnologyHealth Technology EpiTherapeutics ApS is a holding company that develops cancer drugs based on research in the field of epigenetics. Its development programs are focused on enzymes involved in the regulation of transcription in cancer - current programs target histone demethylases and methyltransferases. The firm's regulation is commonly used for post-translational covalent modifications of histones and other chromatin-remodeling complexes, which determines whether a gene is accessible and hence, expressed or repressed. Its covalent modifications involved in epigenetic regulation include deoxyribonucleic acid methylation, histone acetylation, and histone methylation. The company was founded by Kristian Helin, Paul Andreas Compare Cloos, Jesper Aagaard Christensen, Karl Agger, and Klaus Hansen on September 18, 2008 and is headquartered in Greve, Denmark. | Biotechnology | Director/Board Member Director/Board Member | |
Renovacor Holdings, Inc.
 Renovacor Holdings, Inc. BiotechnologyHealth Technology Renovacor, Inc. operates as a preclinical stage biopharmaceutical company focused on developing transformative gene therapy based treatments for cardiovascular disease. The company is headquartered in Philadelphia, PA. | Biotechnology | Director/Board Member Director/Board Member | |
| XILIO THERAPEUTICS, INC. | Pharmaceuticals: Major | President Chairman | |
| INTELLIA THERAPEUTICS, INC. | Biotechnology | Director/Board Member Founder | |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Biotechnology | Corporate Officer/Principal Corporate Officer/Principal | |
| Yale University | College/University | Graduate Degree Graduate Degree | |
Forendo Pharma Oy
 Forendo Pharma Oy Pharmaceuticals: MajorHealth Technology Forendo Pharma Oy provides novel pharmaceutical treatments for endometriosis and low testosterone levels. Its product fispemifene is the first selective estrogen receptor modulator designed only for men, which helps for the treatment of symptoms of low testosterone, in phase II clinical studies in men with secondary hypogonadism; fispemifene has normalized the low testosterone levels. Its 17HSD1-inhibitor focuses on endometriosis, is a potent and selective lead compounds demonstrated in vivo proof of efficacy in disease model of endometriosis. The company was founded by Risto Arvo Sakari Lammintausta in 2013 and is headquartered in Turku, Finland. | Pharmaceuticals: Major | Chairman Director/Board Member | |
Dansk Biotek
 Dansk Biotek Miscellaneous Commercial ServicesCommercial Services Dansk Biotek is an industry association for biotech companies with promoting the biotechnological research, development and production in taking care of corporate interests in this regard, both nationally and internationally. The company was founded in 1987 and is headquartered in Copenhagen, Denmark. | Miscellaneous Commercial Services | Director/Board Member Chairman | |
| ARENA PHARMACEUTICALS | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
| INTERCEPT PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member Chief Tech/Sci/R&D Officer | |
| Massachusetts Institute of Technology | College/University | Graduate Degree Corporate Officer/Principal | |
| PIERIS PHARMACEUTICALS, INC. | Biotechnology | Director of Finance/CFO Chairman | |
| XENETIC BIOSCIENCES, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Masters Business Admin Graduate Degree | |
| University of Copenhagen | College/University | Doctorate Degree Doctorate Degree | |
Aescap Venture Management BV
 Aescap Venture Management BV Investment ManagersFinance Aescap Venture Management BV is an independent venture capital investment firm based in Amsterdam. Aescap was founded in 2005 by Michiel de Haan and Dinko Valerio. Inspired by the name of the Greek god of healthcare, Aesculapiu, the firm's name is an acronym for 'Accelerating European Science Companies and Products.' The firm focuses on developing growth in European firms in the biomedical sector. | Investment Managers | Private Equity Investor | |
| Spinifex Pty Ltd. | Director/Board Member | ||
Levicept Ltd.
 Levicept Ltd. Pharmaceuticals: GenericHealth Technology Levicept Ltd. develops a biological therapy for the treatment of osteoarthritis and chronic pain. Its treatments include p75NTR-Fc and LEVI-04. The company was founded by Simon Lempriere Westbrook on August 23, 2012 and is headquartered in Sandwich, the United Kingdom. | Pharmaceuticals: Generic | Chief Executive Officer | |
Oxford BioTherapeutics Ltd.
 Oxford BioTherapeutics Ltd. Pharmaceuticals: MajorHealth Technology Oxford BioTherapeutics Ltd. develops antibody-based medicines for oncology. The firm offers antibody-based cancer drugs with integrated diagnostics against novel targets. The company was founded by Christian Rohlff in 2003 and is headquartered in Abingdon, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
Tessellate Bio BV
 Tessellate Bio BV BiotechnologyHealth Technology Tessellate Bio BV is a Dutch preclinical stage biotechnology company that focuses on discovering and developing precision oncology medicines. The company is based in Naarden, the Netherlands. The company's mission is to turn cancer patients into cancer survivors by targeting unexplored or difficult to drug pathways beyond HRD. The company is also developing companion diagnostics, including a potentially diagnostic to detect ALT positive cancers. Led by an experienced team of drug hunters, Tessellate Bio is building a pipeline of first-in-class medicines based on cutting-edge research. The company was founded by Hilda A. Pickett and the CEO is Andree Blaukat. | Biotechnology | Director/Board Member | |
| Atlantic Pharmaceuticals (Holdings) Ltd. | Director/Board Member | ||
Ochre Bio Ltd.
 Ochre Bio Ltd. Pharmaceuticals: MajorHealth Technology Ochre Bio Ltd. is a biotechnology company based in Headington, UK. Ochre Bio is focused on developing RNA medicines for chronic liver diseases. The British company uses deep phenotyping, precision RNA medicine, and testing in live human donor livers to develop therapies for important liver health challenges. The company's goal is to develop therapies that increase donor liver supply and reduce cirrhosis complications. The company was founded by Quin Wills and the CEO is Jack O'Meara. | Pharmaceuticals: Major | Chairman | |
Immunocore Ltd.
 Immunocore Ltd. Pharmaceuticals: MajorHealth Technology Part of Immunocore Holdings Plc, Immunocore Ltd. is a British commercial-stage biotechnology company that develops and commercializes transformative medicines to address unmet needs in cancer, infection, and autoimmune disease. The company is based in Oxon, UK. The company has a robust pipeline of wholly owned and partnered programs to address a broad spectrum of disease indications, built on their proprietary soluble TCR bi-specific Immtac® platform. The company was founded in 2007, and the CEO is Bahija Jallal. | Pharmaceuticals: Major | Chief Executive Officer | |
Genomics England Ltd.
 Genomics England Ltd. Miscellaneous Commercial ServicesCommercial Services Genomics England Ltd. runs and delivers 100,000 genomes project. Its flagship project sequences 100,000 genomes from NHS patients with a rare disease and their families, and patients with cancer. The company was founded by Jeremy Hunt on July 5, 2013 and is headquartered in London, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member | |
| Liverpool Health Partners Ltd. | Chairman | ||
| PROTALIX BIOTHERAPEUTICS, INC. | Pharmaceuticals: Major | Chairman | |
| Aescap Life Sciences | Investment Trusts/Mutual Funds | Founder | |
i-Optics BV
 i-Optics BV Medical SpecialtiesHealth Technology i-Optics BV develops and produces eye diagnosis and therapeutic solutions. Its lead product, the EasyScan, that provides non-mydriatic retina imaging camera for the diagnosis of diabetic retinopathy and macular degeneration. The firm engages in the development and marketing of retina and cornea imaging solutions. The company was founded by Michiel Mensink and is headquartered in The Hague, the Netherlands. | Medical Specialties | Director/Board Member | |
National Cancer Institute
 National Cancer Institute Investment Trusts/Mutual FundsMiscellaneous National Cancer Institute provides healthcare services. It specializes in different cancer treatment such as adrenocortical carcinoma, anal cancer, appendix cancer, skin cancer, breast cancer, cardiac tumors, endometrial cancer, and gallbladder cancer. The company was founded in March 1937 and is headquartered in Bethesda, MD. | Investment Trusts/Mutual Funds | Corporate Officer/Principal | |
| JIYA ACQUISITION CORP. | Financial Conglomerates | Director/Board Member |
Statistieken
Internationaal
| Verenigd Koninkrijk | 16 |
| Verenigde Staten | 15 |
| Denemarken | 10 |
| Nederland | 6 |
| Oostenrijk | 2 |
Sectoraal
| Health Technology | 35 |
| Consumer Services | 6 |
| Finance | 5 |
| Commercial Services | 3 |
| Miscellaneous | 3 |
Operationeel
| Director/Board Member | 254 |
| Corporate Officer/Principal | 86 |
| Independent Dir/Board Member | 62 |
| Chief Executive Officer | 54 |
| Chairman | 43 |
Sterkste connecties
| Insiders | |
|---|---|
| Chau Khuong | 38 |
| Nessan Bermingham | 36 |
| Eliot Forster | 35 |
| Carl Goldfischer | 31 |
| Edward Benz | 29 |
| Stephan Christgau | 29 |
| Amit Munshi | 27 |
| Darlene Deptula-Hicks | 24 |
| Patrick Johan Hendrik Krol | 22 |
| Søren Møller | 21 |
| Scott Smith | 21 |
| Pamela Klein | 19 |
| Geoff Race | 17 |
| Hans Schambye | 16 |
| Martin Driscoll | 16 |
- Beurs
- Insiders
- Garrett Winslow
- Bedrijfsconnecties
